Table 2 Pathological classification and number of spectral fingerprint measurements for each tumor type (WHO: World Health Organization; MNI: Montreal Neurological Institute-Hospital; MSH: Mount Sinai Hospital).
From: In situ brain tumor detection using a Raman spectroscopy system—results of a multicenter study
Diagnosis | WHO Grade | Cancer subtype | MNI-H | MSH | ||
|---|---|---|---|---|---|---|
Brain | Tumor | Brain | Tumor | |||
Brain cancer | Grade IV | Glioblastoma | 175 (104) | 343 (249) | 8 (3) | 15 (12) |
Meningioma | Grade I | 192 (100) | 158 (158) | 7 (7) | 4 (4) | |
Grade II | 76 (57) | 20 (20) | 9 (9) | 9 (9) | ||
Lung cancer | Metastatic adenocarcinoma | 72 (57) | 30 (28) | 4 (3) | 2 (2) | |
Metastatic carcinoma | 28 (23) | 11 (8) | 18 (7) | 7 (7) | ||
Breast cancer | Metastatic carcinoma | – | 19 (17) | 9 (8) | 3 (3) | |
Melanoma | Metastatic carcinoma | 19 (17) | 18 (18) | – | – | |
Metastatic melanoma | 19 (2) | – | 8 (6) | – | ||
Kidney cancer | Metastatic carcinoma | – | 9 (9) | – | – | |
Colon cancer | Metastatic adenocarcinoma | – | – | 4 (4) | 3 (3) | |
Prostate cancer | Metastatic adenocarcinoma | – | – | 5 (3) | 7 (6) | |
Endometrial cancer | Metastatic carcinoma | 8 (7) | 10 (6) | – | – | |
Total | 589 (367) | 618 (513) | 72 (50) | 50 (46) | ||
